The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Chariot races were held from the early era until 1204, becoming one of the world's longest continuous sporting events. Mimes, the pantomime and some wild animal shows were prominent until the 6th century. Because Christian bishops and pagan philosophers did not like these activities, the state's funding for them ceased, leading to their decline and a move to private entertainment and sporting. A Persian version of polo introduced by the Crusaders called Tzykanion was played by the nobility and urban aristocracy in major cities during the middle and late eras, as was the sport of jousting introduced from the West. Over time, game boards like tavli became increasingly popular.
=== Detailed expression of Thy-1 === In mice, Thy-1 is also found on thymocytes, peripheral T cells, myoblasts, epidermal cells, and keratinocytes. It is one of the "pan T cell markers"(of mice) like CD2, CD5 and CD28. In humans, Thy-1 is also expressed by endothelial cells, smooth muscle cells, a subset of CD34+ bone marrow cells, and umbilical cord blood-, cardiac fibroblasts, and fetal liver-derived hemopoietic cells. Thy-1 is present on a fraction of brain cells and a fraction of fibroblasts of most vertebrate species studied. Nervous tissue: Thy-1 expression in the nervous system is predominantly neuronal, but some glial cells also express Thy-1 especially at later stages of their differentiation. One study compared Thy-1 expression in four human neuronal cell lines, two neuroglial cell lines, and fresh tumor cells of neuronal origin and found three of the four neuronal cell lines, all of the neuroglial cell lines, and 80% of the tumors to be strongly positive for Thy-1. Brain part specific ELISA reports are available which show highest concentrations of Thy-1 protein in the striatum and hippocampus, followed by the neocortex, cerebellum, spinal cord, and the retina and optic nerve. Thy-1 promoter has often been assumed to be "brain specific". "Neuron specific" mouse Thy-1 promoter has been used to drive "brain specific" forced expression of proteins e.g. mutated Amyloid precursor protein(APP) as transgenic animal models of Alzheimer's disease. Thy-1 expression in the brain is developmentally regulated.
A variety of LSD analogues are known. Many of them retain psychedelic effects similarly to LSD, although most have reduced potency and none are notably more potent than LSD. Examples include ergine (lysergic acid amide; LSA), isoergine (iso-LSA), lysergic acid hydroxyethylamide (LSH), ergonovine (ergometrine), methylergonovine (methylergometrine), methysergide, ETH-LAD, PRO-LAD, AL-LAD, 1-methyl-LSD (MLD-41), MiPLA, and LA-SS-Az (LSZ), among many others. Presumed or known prodrugs of LSD, including 1A-LSD (ALD-52), 1P-LSD, and 1V-LSD, have been developed or encountered. Some non-hallucinogenic LSD analogues, such as lisuride and 2-bromo-LSD (BOL-148), are known as well. They are lower-efficacy serotonin 5-HT2A receptor partial agonists and can notably act as hallucinogen antagonists against LSD. In addition to lysergamide derivatives, simplified or "partial" LSD analogues or seco-LSD compounds, such as NDTDI (8,10-seco-LSD), UCD0179 (3,5-seco-LSD), 10,11-seco-LSD (UCD0121), and N-DEAOP-NMT, are known. A notable bioisostere of LSD is JRT, the isotryptamine analogue of LSD and a psychedelic and psychoplastogen which is under investigation for the potential treatment of schizophrenia. Another notable analogue of LSD is LSD-Quinoline, in which the indole ring within the ergoline ring system is replaced with a quinoline ring.
=== Molecular Characterization === Dynamic light scattering (DLS) Matrix-assisted laser desorption/ionization (MALDI) spectrocosopy Nuclear magnetic resonance (NMR) spectroscopy Size exclusion chromatography (SEC)
Sources: en.wikipedia.org
Alkaline phosphatase: Secreted by osteoblasts during active bone formation; elevated levels indicate increased osteoid production Osteocalcin: A bone-specific protein synthesized by osteoblasts and incorporated into osteoid; serves as a marker of bone formation Type I collagen peptides: Degradation products measured to assess bone turnover
== History == The history of today's Gelita AG in Eberbach dates back to 1875, when the production of gelatin was started in Schweinfurt. Gelita was preceded by the founding of the "Gebrüder Köpff Company", Heinrich Koepff's small tannery, in 1883. Shaken by the economic crisis of the time, Heinrich saw a way out of his misery in gelatin production. The raw material for this could be purchased cheaply, as it was produced in the large tanneries as residual material. With around 60 employees, the factory was already producing photographic gelatin in 1884, which was an important material for the rapidly emerging photography in the 19th century. In 1887, the Koepff brothers acquired the competing company A. & C. Wolff in Heilbronn. Both locations had 320 employees who produced 400 tonnes of gelatin per year. In 1901, a major fire destroyed large parts of the factory. The brothers quarreled over reconstruction. Heinrich went to Heilbronn and Paul Koepff continued to run the rebuilt plant alone under the name Göppinger Gelatin Factory Paul Koepff. In 1911, he sold the factory to DGF AG, which already operated gelatin factories in Schweinfurt and Höchst. Paul Koepff was henceforth on the board of directors and continued to manage his former company as director. In 1929, Paul Koepff jr. took over the management of the Göppingen plant from his father, who died in 1953. The Gelita Brand was introduced in 1934. In 1937, the DGF was accused of violating foreign trade regulations and leading employees were arrested.
=== Achondrogenesis type 2 === Several kinds of mutations in the COL2A1 gene are responsible for achondrogenesis type 2. These include missing pieces of the gene, substitution of the amino acid glycine with another amino acid, or changes that result in truncated proteins. All these mutations disrupt the production of mature type II collagen, affecting tissues rich in this collagen.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.